Labiotech.eu

News and Trends 2 Aug 2022

Glycostem and medac sign deal on AML and MM product

Glycostem Therapeutics B.V. and medac GmbH are to partner to commercialize Glycostem’s lead product, oNKord. oNKord is currently in a phase 1/2 clinical trial across 10 hospitals in five European countries. Glycostem is a Dutch clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf natural killer (NK) cells, and medac is an international pharmaceutical […]

August 2, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 2 Aug 2022

Cellectis gets green light for non-Hodgkin lymphoma trial

French-headquartered gene-editing biotech company Cellectis says the U.S. Food and Drug Administration (FDA) has cleared Cellectis’ Investigational New Drug (IND) application to initiate a phase 1/2a clinical trial of UCART20x22 for patients with relapsed or refractory non-Hodgkin lymphoma (r/r NHL). The company plans to begin enrolling patients in the NatHaLi-01 study in the second half […]

August 2, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 2 Aug 2022

COUR NanoParticle technology halts Type 1 diabetes progression

COUR Pharmaceuticals has published details of a study with the Miller Lab at Northwestern University, looking at type 1 diabetes. COUR develops novel immune-modifying nanoparticles (COUR NanoParticles or CNPs) designed to reprogram the immune system in treating autoimmune disorders. The data demonstrated durable tolerance using its novel platform technology in the non-obese diabetic (NOD) model […]

August 2, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 2 Aug 2022

SNIPR Biome announces new patent granted for applications targeting E. coli infections

SNIPR Biome has today (August 2) announced that it has been granted a patent for medical applications supporting the company’s lead program – a bacteriophage cocktail targeting E.coli infections. Granted by the US Patent and Trademark Office (USPTO), the patent adds to its intellectual property portfolio that contains more than 20 granted patents in the […]

August 2, 2022 - 2 minutesmins - By Liza Laws

News and Trends 2 Aug 2022

Sosei Heptares and AbbVie enter second collaboration targeting neurological diseases

A new drug discovery collaboration has taken place between Japanese Sosei Group Corporation and UK-based Abbvie with the hope of targeting neurological disease. This is the second partnership between the companies and offers the option to license agreement which is aimed at discovering, developing and commercializing small molecules that modulate novel G protein-coupled receptor (GPCR) […]

August 2, 2022 - 2 minutesmins - By Liza Laws

News and Trends 1 Aug 2022

Arecor Therapeutics adds diabetes product to portfolio after significant acquisition

Arecor Therapeutics plc has bought all of Tetris Pharma Ltd shares adding a key commercial diabetes product to its portfolio. The company says as well as expanding its portfolio, the acquisition of the entire issued share capital complements its existing hospital products franchise and will speed up its revenue growth. Injectable products Tetris Pharma has […]

August 1, 2022 - 3 minutesmins - By Liza Laws

News and Trends 1 Aug 2022

FDA puts clinical hold on Beam Theraputics’ cancer therapy

Beam Therapeutics Inc., a U.S. biotech company developing precision genetic medicines through base editing, says the company was informed via email last week that the U.S. Food and Drug Administration (FDA) has placed a hold on the BEAM-201 Investigational New Drug (IND) application for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL)/T cell lymphoblastic […]

August 1, 2022 - 2 minutesmins - By Jim Cornall

Ryvu Therapeutics bags €22M from EIB to work on new cancer treatments

News and Trends 1 Aug 2022

Ipsen and Marengo Therapeutics partner to push immuno-oncology candidates into the clinic

Ipsen and Marengo Therapeutics, Inc. have announced a strategic partnership to advance two of Marengo’s preclinical STAR platform-generated candidates into the clinic. Ipsen also announced it is exercising its option to acquire exclusive worldwide rights to an investigational ERK (extracellular signal-regulated kinase) inhibitor, discovered by AGV Discovery. Ipsen and Marengo Therapeutics details The collaboration between […]

August 1, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 1 Aug 2022

Immutep reports positive data from cancer study

Immutep Limited, an Australian biotech company developing LAG-3-related immunotherapy treatments for cancer and autoimmune disease, has announced new interim data from second-line NSCLC (non-small cell lung cancer) patients (Part B) in its phase 2 TACTI-002 trial. The data was presented at the IASLC 2022 World Conference of Lung Cancer (WCLC 2022) in Vienna, Austria, and […]

August 1, 2022 - 4 minutesmins - By Jim Cornall

In Depth 1 Aug 2022

The biggest US biotech investments in July 2022

The asthma specialist Areteia Therapeutics took the U.S.’ top private biotech investment crown in July 2022, with runners-up including liquid biopsy firm Delfi Diagnostics and the metabolic disease drug developer Carmot Therapeutics. The U.S.’ top private biotech investments in July 2022 didn’t reach the giddy heights of National Resilience’s $625 million Series D round in […]

August 1, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 1 Aug 2022

BioMed X Institute and Merck start new oncology research project

BioMed X, a German independent research institute, has started a new research project ‘Extrachromosomal DNA in Cancer’ (EDC) in collaboration with the Healthcare Business of Merck KGaA, Darmstadt, Germany. The main objective of this research group is to develop an atlas of extrachromosomal DNA (ecDNA) in human cancer tissues and trace back the mechanisms of […]

August 1, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 1 Aug 2022

Zenas BioPharma gets Chinese approval for thyroid eye disease treatment study

Zenas BioPharma has received approval of its Investigational New Drug (IND) application from the National Medical Products Administration (NMPA) of China to start a phase 1/2 clinical study of ZB001 to treat thyroid eye disease (TED). The main objective of the study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZB001. About […]

August 1, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Glycostem and medac sign deal on AML and MM product

Cellectis gets green light for non-Hodgkin lymphoma trial

COUR NanoParticle technology halts Type 1 diabetes progression

SNIPR Biome announces new patent granted for applications targeting E. coli infections

Sosei Heptares and AbbVie enter second collaboration targeting neurological diseases

Arecor Therapeutics adds diabetes product to portfolio after significant acquisition

FDA puts clinical hold on Beam Theraputics’ cancer therapy

Ipsen and Marengo Therapeutics partner to push immuno-oncology candidates into the clinic

Immutep reports positive data from cancer study

The biggest US biotech investments in July 2022

BioMed X Institute and Merck start new oncology research project

Zenas BioPharma gets Chinese approval for thyroid eye disease treatment study

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!